Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months af­ter Gilead gut­ted its rich part­ner­ship with Gala­pa­gos fol­low­ing a bit­ter set­back at the FDA, the Bel­gian biotech is hun­ker­ing down and chop­ping the pipeline in an ef­fort to con­serve cash while their BD team pur­sues a mis­sion to find a “trans­for­ma­tive” deal for the com­pa­ny.

The fil­go­tinib dis­as­ter didn’t war­rant a men­tion as Gala­pa­gos laid out its Dar­win­ian re­struc­tur­ing plans. Forced to make choic­es, the com­pa­ny is ditch­ing its IPF mol­e­cule ’1205, while mov­ing ahead with a Phase II IPF study for its chiti­nase in­hibitor ’4617.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER